The IL1R1 Knockout T-47D Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the human IL1R1 gene in T-47D breast cancer cells. This loss-of-function model is generated through CRISPR/Cas9-mediated gene disruption, producing a heterogeneous pool of edited cells lacking functional IL-1 receptor type 1. The polyclonal format minimizes clonal artifacts and provides a robust platform for reproducible investigation of IL-1 signaling.
The T-47D cell line is a human breast ductal carcinoma isolated from the pleural effusion of a 54-year-old female with metastatic infiltrating ductal carcinoma. This epithelial cell line naturally expresses estrogen receptor (ER), progesterone receptor (PR), and androgen receptor (AR), making it a well-established model for hormone-responsive breast cancer. Its metastatic origin and epithelial characteristics suit it for studying tumor progression and inflammatory signaling.
IL1R1 encodes the interleukin-1 receptor type 1, which transduces signals from IL1A and IL1B. Upon ligand binding, IL1R1 heterodimerizes with IL1RAP, recruiting MYD88 and activating IRAK4 and IRAK1. These kinases associate with TRAF6, triggering TAK1-dependent activation of the IKK complex and MAPKs, including JNK and p38. This leads to NF-??B and AP-1 translocation, inducing transcription of pro-inflammatory mediators such as IL6, IL8, TNF, and COX2. The pathway is regulated by IL1RN, TOLLIP, and IRAK2, and it controls proliferation, apoptosis, and immune responses.
In T-47D breast cancer cells, IL-1 signaling contributes to inflammation-driven tumor progression, migration, and therapeutic resistance. CRISPR/Cas9-mediated IL1R1 knockout abolishes receptor complex formation, preventing MYD88 and IRAK recruitment and downstream activation of NF-??B and MAPK pathways. Consequently, expression of IL-6, IL-8, and other cytokines is attenuated. This knockout model enables investigation of IL-1-mediated effects on breast cancer proliferation, invasion, and hormone receptor signaling.
These polyclonal knockout cells support diverse research applications, including dissection of IL-1 signaling in breast cancer, inflammation-associated tumor progression, drug resistance studies, and validation of IL-1 pathway inhibitors. Representative assays include Western blotting for phospho-p65 and phospho-p38, RT-qPCR for IL6 and IL8, NF-??B luciferase assays, migration/invasion assays, co-immunoprecipitation of IL1R1-IL1RAP, immunofluorescence, flow cytometry, and MTT proliferation assays. The model is suitable for biomarker discovery and therapeutic target evaluation in an ER+ breast cancer context. For additional information or to inquire about custom configurations, please contact Ascent Research.
